Search

Your search keyword '"Imajo, Kento"' showing total 658 results
Start Over Author "Imajo, Kento"
658 results on '"Imajo, Kento"'

1. Head-to-head comparison among FAST, MAST, and multiparametric MRI-based new score in diagnosing at-risk MASH

Author

Imajo, Kento, Saigusa, Yusuke, Kobayashi, Takashi, Nagai, Koki, Nishida, Shinya, Kawamura, Nobuyoshi, Doi, Hiroyoshi, Iwaki, Michihiro, Nogami, Asako, Honda, Yasushi, Kessoku, Takaomi, Ogawa, Yuji, Kirikoshi, Hiroyuki, Kokubu, Shigehiro, Utsunomiya, Daisuke, Takahashi, Hirokazu, Aishima, Shinichi, Sumida, Yoshio, Saito, Satoru, Yoneda, Masato, Dennis, Andrea, Kin, Stella, Andersson, Anneli, and Nakajima, Atsushi

Published
2024
Full Text
View/download PDF

3. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography

Author

Liang, Jia-xu, Ampuero, Javier, Niu, Hao, Imajo, Kento, Noureddin, Mazen, Behari, Jaideep, Lee, Dae Ho, Ehman, Richard L, Rorsman, Fredrik, Vessby, Johan, Lacalle, Juan R, Mózes, Ferenc E, Pavlides, Michael, Anstee, Quentin M, Harrison, Stephen A, Castell, Javier, Loomba, Rohit, Romero-Gómez, Manuel, and Investigators, LITMUS Consortium

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Chronic Liver Disease and Cirrhosis, Biomedical Imaging, Liver Disease, Digestive Diseases, Obesity, 4.2 Evaluation of markers and technologies, Oral and gastrointestinal, Humans, Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques, Liver Cirrhosis, Fibrosis, ROC Curve, Magnetic Resonance Imaging, Liver, Elastography, Magnetic Resonance, NAFLD, NASH, GGT, LITMUS Consortium Investigators, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsWe conducted an individual patient data meta-analysis to establish stiffness cut-off values for magnetic resonance elastography (MRE) in staging liver fibrosis and to assess potential confounding factors.MethodsA systematic review of the literature identified studies reporting MRE data in patients with NAFLD. Data were obtained from the corresponding authors. The pooled diagnostic cut-off value for the various fibrosis stages was determined in a two-stage meta-analysis. Multilevel modelling methods were used to analyse potential confounding factors influencing the diagnostic accuracy of MRE in staging liver fibrosis.ResultsEight independent cohorts comprising 798 patients were included in the meta-analysis. The area under the receiver operating characteristic curve (AUROC) for MRE in detecting significant fibrosis was 0.92 (sensitivity, 79%; specificity, 89%). For advanced fibrosis, the AUROC was 0.92 (sensitivity, 87%; specificity, 88%). For cirrhosis, the AUROC was 0.94 (sensitivity, 88%, specificity, 89%). Cut-offs were defined to explore concordance between MRE and histopathology: ≥F2, 3.14 kPa (pretest probability, 39.4%); ≥F3, 3.53 kPa (pretest probability, 24.1%); and F4, 4.45 kPa (pretest probability, 8.7%). In generalized linear mixed model analysis, histological steatohepatitis with higher inflammatory activity (odds ratio 2.448, 95% CI 1.180-5.079, p 120U/L) (odds ratio 3.388, 95% CI 1.577-7.278, p

Published
2023

4. M‐PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis

Author

Imajo, Kento, Saigusa, Yusuke, Kobayashi, Takashi, Nagai, Koki, Nishida, Shinya, Kawamura, Nobuyoshi, Doi, Hiroyoshi, Iwaki, Michihiro, Nogami, Asako, Honda, Yasushi, Kessoku, Takaomi, Ogawa, Yuji, Kirikoshi, Hiroyuki, Yasuda, Satoshi, Toyoda, Hidenori, Hayashi, Hideki, Kokubu, Shigehiro, Utsunomiya, Daisuke, Takahashi, Hirokazu, Aishima, Shinichi, Kim, Beom Kyung, Tamaki, Nobuharu, Saito, Satoru, Yoneda, Masato, Loomba, Rohit, and Nakajima, Atsushi

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Biomedical Imaging, Hepatitis, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Clinical Research, 4.2 Evaluation of markers and technologies, Oral and gastrointestinal, active fibrotic NASH, F-CAST, FAST, M-PAST, MAST
Abstract

BackgroundClinical trials enroll patients with active fibrotic nonalcoholic steatohepatitis (NASH) (nonalcoholic fatty liver disease [NAFLD] activity score ≥ 4) and significant fibrosis (F ≥ 2); however, screening failure rates are high following biopsy. We developed new scores to identify active fibrotic NASH using FibroScan and magnetic resonance imaging (MRI).MethodsWe undertook prospective primary (n = 176), retrospective validation (n = 169), and University of California San Diego (UCSD; n = 234) studies of liver biopsy-proven NAFLD. Liver stiffness measurement (LSM) using FibroScan or magnetic resonance elastography (MRE), controlled attenuation parameter (CAP), or proton density fat fraction (PDFF), and aspartate aminotransferase (AST) were combined to develop a two-step strategy-FibroScan-based LSM followed by CAP with AST (F-CAST) and MRE-based LSM followed by PDFF with AST (M-PAST)-and compared with FibroScan-AST (FAST) and MRI-AST (MAST) for diagnosing active fibrotic NASH. Each model was categorized using rule-in and rule-out criteria.ResultsAreas under receiver operating characteristic curves (AUROCs) of F-CAST (0.826) and M-PAST (0.832) were significantly higher than those of FAST (0.744, p = 0.004) and MAST (0.710, p

Published
2023

6. Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD

Author

Tamaki, Nobuharu, Imajo, Kento, Sharpton, Suzanne R, Jung, Jinho, Sutter, Nancy, Kawamura, Nobuyoshi, Yoneda, Masato, Valasek, Mark A, Behling, Cynthia, Sirlin, Claude B, Kurosaki, Masayuki, Izumi, Namiki, Nakajima, Atsushi, and Loomba, Rohit

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Biomedical Imaging, Digestive Diseases, Clinical Research, Chronic Liver Disease and Cirrhosis, Liver Disease, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Humans, Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, Elasticity Imaging Techniques, Fibrosis, Predictive Value of Tests, Biopsy, Liver, Nonalcoholic Fatty Liver Disease, Advanced Fibrosis, Magnetic Resonance Elastography, FIB-4, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsA two-step strategy combining a serum marker and magnetic resonance elastography (MRE) for detecting advanced fibrosis (stage 3-4) among patients with nonalcoholic fatty liver disease (NAFLD) has been proposed, but its diagnostic accuracy has not been evaluated. In this multicenter study, we aimed to investigate the diagnostic accuracy of a two-step strategy including Fibrosis-4 (FIB-4) followed by MRE.MethodsIn this multicenter study, 806 patients with biopsy-proven NAFLD who underwent contemporaneous MRE were enrolled and randomly assigned to training and validation cohorts. As a first step, patients with FIB-4

Published
2023

7. Magnetic resonance elastography plus Fibrosis‐4 versus FibroScan–aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH‐related fibrosis

Author

Tamaki, Nobuharu, Imajo, Kento, Sharpton, Suzanne, Jung, Jinho, Kawamura, Nobuyoshi, Yoneda, Masato, Valasek, Mark A, Behling, Cynthia, Sirlin, Claude B, Nakajima, Atsushi, and Loomba, Rohit

Subjects
Chronic Liver Disease and Cirrhosis, Clinical Research, Liver Disease, Digestive Diseases, Aspartate Aminotransferases, Biopsy, Cohort Studies, Elasticity, Elasticity Imaging Techniques, Female, Humans, Japan, Liver, Liver Cirrhosis, Magnetic Resonance Imaging, Male, Middle Aged, Multimodal Imaging, Non-alcoholic Fatty Liver Disease, Patient Selection, Predictive Value of Tests, ROC Curve, Severity of Illness Index, Medical Biochemistry and Metabolomics, Clinical Sciences, Immunology, Gastroenterology & Hepatology
Abstract

Background and aimsPatients with NAFLD with significant hepatic fibrosis (Stage ≥ 2) are at increased risk of liver-related morbidity and are candidates for pharmacologic therapies. In this study, we compared the diagnostic accuracy of MEFIB (the combination of magnetic resonance elastography [MRE] and Fibrosis-4 [FIB-4]) and FAST (FibroScan-aspartate aminotransferase; combined liver stiffness measurement by vibration-controlled transient elastography, controlled attenuation parameter, and aspartate aminotransferase) for detecting significant fibrosis.Approach and resultsThis prospective cohort study included 234 consecutive patients with NAFLD who underwent liver biopsy, MRE, and FibroScan at the University of California San Diego (UCSD cohort) and an independent cohort (N = 314) from Yokohama City University, Japan. The primary outcome was diagnostic accuracy for significant fibrosis (Stage ≥ 2). The proportions of significant fibrosis in the UCSD and Yokohama cohorts were 29.5% and 66.2%, respectively. Area under the receiver operating characteristic curve (95% CI) of MEFIB (0.860 [0.81-0.91]) was significantly higher than that of FAST (0.757 [0.69-0.82]) in the UCSD cohort (p = 0.005), with consistent results in the Yokohama cohort (AUROC, 0.899 [MEFIB] versus 0.724 [FAST]; p

Published
2022

8. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Author

Nakajima, Atsushi, Eguchi, Yuichiro, Yoneda, Masato, Imajo, Kento, Tamaki, Nobuharu, Suganami, Hideki, Nojima, Toshiaki, Tanigawa, Ryohei, Iizuka, Masakazu, Iida, Yuki, and Loomba, Rohit

Subjects
Digestive Diseases, Hepatitis, Chronic Liver Disease and Cirrhosis, Clinical Trials and Supportive Activities, Liver Disease, Biomedical Imaging, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Oral and gastrointestinal, Animals, Benzoxazoles, Butyrates, Double-Blind Method, Humans, Liver, Mice, Non-alcoholic Fatty Liver Disease, PPAR alpha, Clinical Sciences, Pharmacology and Pharmaceutical Sciences, Gastroenterology & Hepatology
Abstract

BackgroundPemafibrate is a novel, selective peroxisome proliferator-activated receptor α modulator (SPPARMα). In mice, Pemafibrate improved the histological features of non-alcoholic steatohepatitis (NASH). In patients with dyslipidaemia, it improved serum alanine aminotransferase (ALT).AimsTo evaluate the efficacy and safety of Pemafibrate in patients with high-risk, non-alcoholic fatty liver disease (NAFLD).MethodsThis double-blind, placebo-controlled, randomised multicentre, phase 2 trial randomised 118 patients (1:1) to either 0.2 mg Pemafibrate or placebo, orally, twice daily for 72 weeks. The key inclusion criteria included liver fat content of ≥10% by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF); liver stiffness of ≥2.5 kPa, by magnetic resonance elastography (MRE); and elevated ALT levels. The primary endpoint was the percentage change in MRI-PDFF from baseline to week 24. The secondary endpoints included MRE-based liver stiffness, ALT, serum liver fibrosis markers and lipid parameters.ResultsThere was no significant difference between the groups in the primary endpoint (-5.3% vs -4.2%; treatment difference -1.0%, P = 0.85). However, MRE-based liver stiffness significantly decreased compared to placebo at week 48 (treatment difference -5.7%, P = 0.036), and was maintained at week 72 (treatment difference -6.2%, P = 0.024), with significant reduction in ALT and LDL-C. Adverse events were comparable between the treatment groups and therapy was well tolerated.ConclusionsPemafibrate did not decrease liver fat content but had significant reduction in MRE-based liver stiffness. Pemafibrate may be a promising therapeutic agent for NAFLD/NASH, and also be a candidate for combination therapy with agents that reduce liver fat content. ClinicalTrials.gov, number: NCT03350165.

Published
2021

9. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis

Author

Jung, Jinho, Loomba, Rohan R, Imajo, Kento, Madamba, Egbert, Gandhi, Sanil, Bettencourt, Ricki, Singh, Seema, Hernandez, Carolyn, Valasek, Mark A, Behling, Cynthia, Richards, Lisa, Fowler, Katie, Sirlin, Claude B, Nakajima, Atsushi, and Loomba, Rohit

Subjects
Digestive Diseases, Hepatitis, Clinical Research, Liver Disease, Chronic Liver Disease and Cirrhosis, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Aged, California, Cross-Sectional Studies, Elasticity Imaging Techniques, Female, Humans, Japan, Liver Cirrhosis, Magnetic Resonance Imaging, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Predictive Value of Tests, Prospective Studies, fatty liver, hepatic fibrosis, liver function test, liver imaging, Clinical Sciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology
Abstract

ObjectivePatients with non-alcoholic fatty liver disease (NAFLD) with ≥stage 2 fibrosis are at increased risk for liver-related mortality and are candidates for pharmacological therapies for treatment of NAFLD. The aim of this prospective cohort study is to examine the diagnostic accuracy of MR elastography (MRE) combined with fibrosis-4 (FIB-4) in diagnosing ≥stage 2 fibrosis (candidates for pharmacological therapies).DesignThis is a cross-sectional analysis of a prospective cohort (University of California at San Diego (UCSD)-NAFLD) including 238 consecutive patients with contemporaneous MRE and biopsy-proven NAFLD. Non-alcoholic steatohepatitis-Clinical Research Network-Histologic Scoring System was used to assess histology. The radiologist and pathologist were blinded to clinical, pathological and imaging data, respectively. Receiver operating characteristics (ROCs) were determined to examine the diagnostic accuracy of MRE and FIB-4 for diagnosis of ≥stage 2 fibrosis in NAFLD. We then validated these findings in an independent validation cohort derived from Yokohama City University in Japan (Japan-NAFLD Cohort; N=222 patients).ResultsIn the UCSD-NAFLD (training) Cohort, MRE demonstrated a clinically significant diagnostic accuracy for the detection of ≥stage 2 fibrosis with an area under the ROC curve (AUROC) of 0.93 (95% CI 0.90 to 0.97) vs FIB-4 with an AUROC of 0.78 (95% CI 0.71 to 0.85), which was both clinically and statistically significant (p

Published
2021

11. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Author

Abdelmalek, Manal F., Sanyal, Arun J., Nakajima, Atsushi, Neuschwander-Tetri, Brent A., Goodman, Zachary D., Lawitz, Eric J., Harrison, Stephen A., Jacobson, Ira M., Imajo, Kento, Gunn, Nadege, Halegoua-DeMarzio, Dina, Akahane, Takemi, Boone, Bradly, Yamaguchi, Masayuki, Chatterjee, Arkendu, Tirucherai, Giridhar S., Shevell, Diane E., Du, Shuyan, Charles, Edgar D., and Loomba, Rohit

Published
2024
Full Text
View/download PDF

12. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Author

Loomba, Rohit, Sanyal, Arun J., Nakajima, Atsushi, Neuschwander-Tetri, Brent A., Goodman, Zachary D., Harrison, Stephen A., Lawitz, Eric J., Gunn, Nadege, Imajo, Kento, Ravendhran, Natarajan, Akahane, Takemi, Boone, Bradly, Yamaguchi, Masayuki, Chatterjee, Arkendu, Tirucherai, Giridhar S., Shevell, Diane E., Du, Shuyan, Charles, Edgar D., and Abdelmalek, Manal F.

Published
2024
Full Text
View/download PDF

13. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants

Author

Hsu, Cynthia, Caussy, Cyrielle, Imajo, Kento, Chen, Jun, Singh, Siddharth, Kaulback, Kellee, Le, Minh-Da, Hooker, Jonathan, Tu, Xin, Bettencourt, Ricki, Yin, Meng, Sirlin, Claude B, Ehman, Richard L, Nakajima, Atsushi, and Loomba, Rohit

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Clinical Trials and Supportive Activities, Clinical Research, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Diagnostic Tests, Routine, Elasticity Imaging Techniques, Female, Humans, Liver Cirrhosis, Magnetic Resonance Imaging, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, ROC Curve, Magnetic Resonance Elastography, Fibroscan, Transient Elastography, NAFLD, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsMagnetic resonance elastography (MRE) and transient elastography (TE) are noninvasive techniques for detection of liver fibrosis. Single-center studies have compared the diagnostic performance of MRE vs TE in patients with nonalcoholic fatty liver disease (NAFLD). We conducted a pooled analysis of individual participant data from published studies to compare the diagnostic performance of MRE vs TE for staging of liver fibrosis in patients with NAFLD, using liver biopsy as reference.MethodsWe performed a systematic search of publication databases, from 2005 through 2017. We identified 3 studies of adults with NAFLD who were assessed by MRE, TE, and liver biopsy. In a pooled analysis, we calculated the cluster-adjusted area under the curve (AUROC) of MRE and TE for the detection of each stage of fibrosis. AUROC comparisons between MRE and TE were performed using the Delong test.ResultsOur pooled analysis included 230 participants with biopsy-proven NAFLD with mean age of 52.2±13.9 years and a body mass index of 31.9±7.5 kg/m2. The proportions of patients with fibrosis of stages 0, 1, 2, 3, and 4 were: 31.7%, 27.8%, 15.7%, 13.9%, and 10.9%, respectively. The AUROC of TE vs MRE for detection of fibrosis stages ≥1 was 0.82 (95% CI, 0.76-0.88) vs 0.87 (95% CI, 0.82-0.91) (P=.04); for stage≥ 2 was 0.87 (95% CI, 0.82-0.91) vs 0.92 (95% CI, 0.88-0.96) (P=.03); for stage ≥3 was 0.84 (95% CI, 0.78-0.90) vs 0.93 (95% CI, 0.89-0.96) (P=.001); for stage ≥ 4 was 0.84 (95% CI, 0.73-0.94) vs 0.94 (95% CI, 0.89-0.99) (P=.005).ConclusionIn a pooled analysis of data from individual participants with biopsy-proven NAFLD, we found MRE to have a statistically significantly higher diagnostic accuracy than TE in detection of each stage of fibrosis. MRE and TE each have roles in detection of fibrosis in patients with NAFLD, depending upon the level of accuracy desired.

Published
2019

19. Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study.

Author

Zhang, Ying, Numata, Kazushi, Imajo, Kento, Uojima, Haruki, Funaoka, Akihiro, Komiyama, Satoshi, Ogushi, Katsuaki, Chuma, Makoto, Irie, Kuniyasu, Kokubu, Shigehiro, Yoneda, Masato, Kobayashi, Takashi, Hidaka, Hisashi, Fukushima, Taito, Kobayashi, Satoshi, Morimoto, Manabu, Kagawa, Tatehiro, Hattori, Nobuhiro, Watanabe, Tsunamasa, and Iwase, Shigeru

Abstract

Aim: This study aims to evaluate the efficacy and safety of lenvatinib radiofrequency ablation (RFA) sequential therapy for certain hepatocellular carcinoma (HCC) patients. Methods: One hundred and nineteen patients with unresectable HCC in the intermediate stage with Child–Pugh A were retrospectively recruited in a multicenter setting. Those in the lenvatinib RFA sequential therapy group received lenvatinib initially, followed by RFA and the retreatment with lenvatinib. The study compared overall survival (OS), progression‐free survival (PFS), tumor response, and adverse events (AEs) between patients undergoing sequential therapy and lenvatinib monotherapy. Results: After propensity score matching, 25 patients on sequential therapy and 50 on monotherapy were evaluated. Independent factors influencing OS were identified as sequential therapy, modified albumin–bilirubin (mALBI) grade, and relative dose intensity (%) with hazard ratios (HRs) of 0.381 (95% confidence interval [CI], 0.186–0.782), 2.220 (95% CI, 1.410–3.493), and 0.982 (95% CI, 0.966–0.999), respectively. Stratified analysis based on mALBI grades confirmed the independent influence of treatment strategy across all mALBI grades for OS (HR, 0.376; 95% CI, 0.176–0.804). Furthermore, sequential therapy was identified as an independent factor of PFS (HR, 0.382; 95% CI, 0.215–0.678). Sequential therapy significantly outperformed monotherapy on survival benefits (OS: 38.27 vs. 18.96 months for sequential therapy and monotherapy, respectively, p = 0.004; PFS: 13.80 vs. 5.32 months for sequential therapy and monotherapy, respectively, p < 0.001). Sequential therapy was significantly associated with complete response by modified Response Evaluation Criteria in Solid Tumors (odds ratio, 63.089). Ten of 119 patients experienced grade 3 AEs, with no AE beyond grade 3 observed. Conclusion: Lenvatinib RFA sequential therapy might offer favorable tolerability and potential prognostic improvement compared to lenvatinib monotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study

Author

Tan, Eunice Xiang-Xuan, Lee, Jonathan Wei-Jie, Jumat, Nur Halisah, Chan, Wah-Kheong, Treeprasertsuk, Sombat, Goh, George Boon-Bee, Fan, Jian-Gao, Song, Myeong Jun, Charatcharoenwitthaya, Phunchai, Duseja, Ajay, Imajo, Kento, Nakajima, Atsushi, Seki, Yosuke, Kasama, Kazunori, Kakizaki, Satoru, Lesmana, Laurentius A., Zheng, Kenneth I., Zheng, Ming-Hua, Koh, Calvin J., Ho, Khek-Yu, Goh, Khean-Lee, Wong, Vincent Wai-Sun, and Dan, Yock-Young

Published
2022
Full Text
View/download PDF

24. WED-283 The distribution of fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction associated steatotic liver disease in the general population

Author

Ogawa, Yuji, primary, Tomeno, Wataru, additional, Yasushi, Imamura, additional, Baba, Masaru, additional, Ueno, Takato, additional, Kobayashi, Takashi, additional, Iwaki, Michihiro, additional, Nogami, Asako, additional, Kessoku, Takaomi, additional, Honda, Yasushi, additional, Imajo, Kento, additional, Kawanaka, Miwa, additional, Hisatomi, Mitsurou, additional, Takeuchi, Mamiko, additional, Honda, Takashi, additional, Tatsuta, Miwa, additional, Morishita, Asahiro, additional, Mikami, Shigeru, additional, Furuya, Ken, additional, Manabe, Noriaki, additional, Kamada, Tomoari, additional, Kawaguchi, Takumi, additional, Yoneda, Masato, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2024
Full Text
View/download PDF

26. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan

Author

Yoneda, Masato, Yamamoto, Takuma, Honda, Yasushi, Imajo, Kento, Ogawa, Yuji, Kessoku, Takaomi, Kobayashi, Takashi, Nogami, Asako, Higurashi, Takuma, Kato, Shingo, Hosono, Kunihiro, Saito, Satoru, and Nakajima, Atsushi

Published
2021
Full Text
View/download PDF

27. A Handheld Ultrasound Device Can Predict Constipation with Rectal Fecal Retention in a Palliative Care Setting.

Author

Yamamoto, Atsushi, Kessoku, Takaomi, Ogata, Tomoki, Jono, Tsumugi, Takahashi, Kota, Tanaka, Kosuke, Suzuki, Ko, Takeda, Yuma, Ozaki, Anna, Kasai, Yuki, Okubo, Naoki, Iwaki, Michihiro, Kobayashi, Takashi, Misawa, Noboru, Yoshihara, Tsutomu, Suzuki, Akihiro, Fuyuki, Akiko, Hasegawa, Sho, Imajo, Kento, and Kobayashi, Noritoshi

Subjects
DIGITAL rectal examination, SYMPTOMS, COMPUTED tomography, PALLIATIVE treatment, CONSTIPATION
Abstract

Although handheld ultrasound devices (HUDs) are commonplace, their ability to diagnose fecal retention (FR) remains unclear. This prospective observational study examined HUDs' usefulness in diagnosing FR in patients with constipation in a palliative care setting. Between 10 December 2020 and 30 June 2022, we compared rectal ultrasonographic findings obtained using HUDs with clinical manifestations in 64 males and 70 females (48%, 52%, 68 ± 11 years old) with constipation who had undergone computed tomography (CT). FR was diagnosed using a HUD and compared with CT and digital rectal examination (DRE) results. In total, 42 (31%), 42 (31%), and 41 (31%) patients were diagnosed using HUDs, CT, and DRE, respectively. Thirty-nine (93%) patients in the CT group were also diagnosed with FR using HUDs. A total of 89 of 92 patients with a negative CT diagnosis also had a negative HUD diagnosis. Among the 41 patients in the DRE group, 37 were also diagnosed with FR using HUDs. Among 93 patients with a negative DRE diagnosis, 86 had a negative HUD diagnosis. The sensitivity, specificity, positive predictive value, and negative predictive value of HUDs for CT were 93%, 97%, 93%, and 97%, respectively. Those of HUDs for DRE were 88%, 94%, 86%, and 95%, respectively. The concordance rates for FR diagnosis were 128/134 for CT and HUDs and 123/134 for DRE and HUDs. HUD was useful for diagnosing FR in this setting. HUDs could provide valuable support for appropriate treatment selection. Developing a constipation treatment algorithm based on rectal ultrasonographic findings is warranted in the future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial

Author

Kessoku, Takaomi, Imajo, Kento, Kobayashi, Takashi, Ozaki, Anna, Iwaki, Michihiro, Honda, Yasushi, Kato, Takayuki, Ogawa, Yuji, Tomeno, Wataru, Kato, Shingo, Higurashi, Takuma, Yoneda, Masato, Kirikoshi, Hiroyuki, Kubota, Kazumi, Taguri, Masataka, Yamanaka, Takeharu, Usuda, Haruki, Wada, Koichiro, Kobayashi, Noritoshi, Saito, Satoru, and Nakajima, Atsushi

Published
2020
Full Text
View/download PDF

30. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Author

Gadano, Adrian, Martins, Marcelo, Angus, Peter, Bate, John, Danta, Mark, George, Jacob, Hodge, Alexander, Kontorinis, Nickolas, Roberts, Stuart, Sanagapalli, Santosh, Skoien, Richard, Thompson, Alexander, Zekry, Amany, Stauber, Rudolf, Trauner, Michael, Moreno, Christophe, Reynaert, Hendrik, Verbeke, Len, Silva, Mario Reis Alvares da, Parise, Edison, Oliveira, Claudia Pinto Marques Souza de, Araujo, Roberta Chaves, Martinelli, Ana de Lourdes Candolo, Borman, Meredith, Chandok, Natasha, Elkhashab, Magdy, Fraser, Hughie, Kaita, Kelly, Ma, Mang, Marotta, Paul, Ramji, Alnoor, Tam, Edward, Yoshida, Eric, Swain, Mark, Sebastiani, Giada, Petrunia, Denis, Abergel, Armando, Anty, Rodolphe, Bourlière, Marc, Boursier, Jérôme, Bureau, Christophe, Castera, Laurent, Habersetzer, François, Hézode, Christophe, Ledinghen, Victor De, Leroy, Vincent, Loustaud-Ratti, Véronique, Mathurin, Philippe, Pol, Stanislas, Zoulim, Fabien, Hinrichsen, Holger, Ingiliz, Patrick, Lammert, Frank, Manns, Michael, Schattenberg, Jörn, Schiefke, Ingolf, Trautwein, Christian, Zeuzem, Stefan, Hui, Aric, Li, King-Kong, Wong, Vincent, Acharya, Subrat, Chowdhury, Abhijit, Duseja, Ajay, Kapoor, Dharmesh, Mukewar, Shrikant, Sarin, Shiv, Shah, Samir, Shalimar, Sood, Ajit, Tantry, BV, Ben-Ari, Ziv, Katchman, Helena, Safadi, Rifaat, Veitsman, Ella, Zuckerman, Eli, Brunetto, Maurizia, Lampertico, Pietro, Mangia, Alessandra, Akahane, Takemi, Akuta, Norio, Eguchi, Yuichiro, Fujiyama, Shigetoshi, Genda, Takuya, Hiasa, Yoichi, Ido, Akio, Ikeda, Fusao, Ikegami, Tadashi, Imajo, Kento, Itoh, Yoshito, Iwasa, Motoh, Karino, Yoshiyasu, Kato, Naoya, Kawaguchi, Takumi, Kawanaka, Miwa, Kido, Masahiro, Kobayashi, Tomoo, Kurosaki, Masayuki, Matsuzaki, Yasushi, Mita, Eiji, Mizukoshi, Eishiro, Nakahara, Takashi, Nomura, Hideyuki, Notsumata, Kazuo, Okanoue, Takeshi, Saito, Satoshi, Sakugawa, Hiroshi, Suzuki, Yoshiyuki, Takaguchi, Koichi, Takaki, Akinobu, Takashima, Tomoyuki, Tanaka, Saiyu, Tsuji, Keiji, Ueno, Yoshiyuki, Umemura, Takeji, Uto, Hirofumi, Yamashita, Nobuyuki, Yanase, Mikio, Yatsuhashi, Hiroshi, Yoneda, Masashi, Chan, Wah Kheong, Tan, Soek Siam, Garza, Laura Cisneros, Ladron De Guevara Cetina, Alma, Angeles, Rocio Guadalupe Vargas, Silva, Francisca Martinez, Van Erpecum, Karel, Orr, David, Jabłkowski, Maciej, Jaroszewicz, Jerzy, Ramos, Jose, Ahmed, Taufique, Ang, Tiing, Dan, Yock young, Goh, Boon Bee, Kaliyaperumal, Kalaiyarasi, Yip, Cherng Hann, Baik, Soon Koo, Jang, Byoung Kuk, Jun, Dae Won, Kim, Won, Kim, Hyung Joon, Kim, Ji Hoon, Lee, Kwan Sik, Lee, Chun Kyon, Lim, Young-Suk, Park, Jun Yong, Tak, Won Young, Augustin, Salvador, Perez, Salvador Benlloch, Caballeria, Juan, Luis, Jose, Panero, Calleja, Rodríguez, Jose Carrión, Garcia, Javier Crespo, Samaniego, Javier Garcia, Gibert, Pere Ginès, Prieto, Martin, Gomez, Manuel Romero, Turnes, Juan, Dufour, Jean-Francois, Moriggia, Alberto, Sheen, I-Shyan, Kao, Jia-Horng, Cheng, Pin-Nan, Huang, Jee-Fu, Yang, Sheng-Shun, Su, Wei-Wen, Chen, Chi-Yi, Chien, Rong-Nan, Lo, Gin-Ho, Chu, Chi-Jen, Wang, Horng-Yuan, Hu, Jui-Ting, Huang, Yi Wen, Agarwal, Kosh, Allison, Michael, Anstee, Quentin, Austin, Andrew, Fowell, Andrew, Ch'ng, Chin Lye, Manousou, Pinelopi, Newsome, Philip, Ryder, Stephen, Shankar, Arun, Abdelmalek, Manal, Abrams, Gary, Aguilar, Humberto, Alam, Imtiaz, Alba, Laura, Alkhouri, Naim, Allen, Alina, Aqel, Bashar, Balart, Luis, Barritt, A. Sidney, IV, Behari, Jaideep, Bennett, Michael, Bernstein, David, Bhandari, Bal Raj, Bonacini, Maurizio, Borg, Brian, Brown, Kimberly, Bzowej, Natalie, Caldwell, Stephen, Chami, Tawfik, Coates, Allan, Cueli, Adolfo, Davis, Mitchell, deLemos, Andrew, Desai, Archita, Dunn, Winston, Ferreira, Nelson, Fine, Michael, Firpi-Morell, Roberto, Freedland, Curtis, Freilich, Bradley, Fuchs, Michael, Galambos, Michael, Gallegos-Orozco, Juan, Galler, Greg, Ghali, Maged, Ghalib, Reem, Gill, Satinder, Gillis, Marcum, Gilroy, Richard, Gordon, Stuart, Gunn, Nadege, Halegoua-DeMarzio, Dina, Hassan, Mohamed, Hassanein, Tarek, Herring, Robert, Jr., Hong, John, Huang, Jonathan, Kabler, Heidi, Kayali, Zeid, Knapple, Whitfield, Kolli, Geetha, Kowdley, Kris, Krause, Richard, Lawitz, Eric, Lidofsky, Steven, Lim, Joseph, Lipkis, Donald, Loomba, Rohit, Mahgoub, Amar, Malespin, Miguel, Manch, Richard, Mannis, Steven, Manos, Paul, McDonald, Thomas, McKenzie, Mark, Mena, Edward, Merriman, Raphael, Moehlen, Martin William, Montgomery, Richard, Murphy, Robert, Natarajan, Yamini, Neff, Guy, Noureddin, Mazen, Ortiz-Lasanta, Grisell, Pagadala, Mangesh, Patel, Keyur, Patton, Heather, Peyton, Adam, Pimstone, Neville, Poulos, John, Pound, David, Pyrsopoulos, Nikolaos, Rafiq, Nila, Ravendhran, Natarajan, Ravinuthala, Ravi, Reddy, K. Rajendar, Reindollar, Robert, Reynolds, Justin, Rinella, Mary, Rizvi, Syed, Rockey, Don, Rodriguez-Perez, Federico, Ruane, Peter, Rubin, Raymond, Ryan, Michael, Saeian, Kia, Sanyal, Arun, Sarkar, Souvik, Scanga, Andrew, Schiff, Eugene, Schmidt, Warren, Schneider, Jeffrey, Sepe, Thomas, Shah, Dhiren, Shaikh, Obaid, Shankar, Uday, Sheikh, Aasim, Sheikh, Muhammad, Sherman, Kenneth, Shiffman, Mitchell, Siddique, Asma, Smith, Matthew, Suarez, Rosa, Talal, Andrew, Te, Helen, Tekola, Bezawit, Tetri, Brent, Thuluvath, Paul, Toro, Doris, Torres, Dawn, Trinh, Huy, Trotter, James, Vento, Angel, Vierling, John, Vuppalanchi, Raj, Waters, Michael, Weisberg, Ilan, Wieland, Amanda, Williams, Alonzo, Younes, Ziad, Adams, Leon, Harding, Damian, Hodge, Alex, Kontorinis, Nick, Strasser, Simone, Thompson, Alex, Horsmans, Yves, Steenkiste, Christophe Van, Bailey, Robert, Giard, Jeanne-Marie, Montano-Loza, Aldo, Puglia, Marco, Tsoi, Keith, Larrey, Dominique, Nguyen-Khac, Eric, Ratziu, Vlad, Spengler, Ulrich, Wiegand, Johannes, Hui, Aric Josun, Acharya, Subrat Kumar, Sarin, Shiv Kumar, Tantry, Vishwanath, Braun, Marius, Hazzan, Rawi, Lurie, Yoav, Colombo, Massimo, Fujii, Hideki, Hashimoto, Etsuko, Kato, Masaki, Ogawa, Koji, Takehara, Tetsuo, Tokushige, Katsutoshi, Garza, Laura Esthela Cisneros, Ladrón De Guevara, Alma Laura, Schultz, Michael, Janczewska, Ewa, Toro, Doris H., Jeong, Sook-Hyang, Kim, Yoon Jun, Lee, Jin-Woo, Ang, Tiing Leong, Bee, George Goh Boon, Benlloch, Salvador, Caballería, Juan, Calleja, José Luis, Rodríguez, Jose A. Carrión, Crespo, Javier, Diago, Moises, Fernandez-Rodriguez, Conrado, García-Samaniego, Javier, Ginès, Pere, Romero, Manuel, Dufour, Jean-François, Alazawi, William, Ch'ng, Chin-Lye, Forton, Daniel, Priest, Matthew, Sheridan, David, Ankoma-Sey, Victor, Balakrishnan, Maya, Bambha, Kiran, Barritt, A. Sidney, Bhandari, Bal, Brandman, Danielle, Chang, Charissa, Corey, Kathleen, Feldman, Michael, Gholam, Pierre, Goff, John, Marzio, Dina Halegoua-De, Harrison, Stephen, Hellstern, Paul, Jr., Herring, Robert, Iyer, Rajalakshmi, Jakiche, Antoine, Kohli, Anita, Krok, Karen, Kugelmas, Marcelo, Kumar, Sonal, Lai, Michelle, Mahmoud, Mitchell, Mantry, Parvez, Marsano, Luis, Nguyen, Tuan, Park, James, Patton, Heather M., Pockros, Paul, Reddy, Rajender, Rodriguez, Miguel, Sarles, Harry, Satapathy, Sanjaya, Sedghi, Shahriar, Shah, Nikunj, Sheikh, Muhammad Yasin, Sigal, Samuel, Stanca, Carmen, Steinbook, Michael, Szabo, Gyongyi, Terrault, Norah, Tong, Myron, Victor, David, Zervos, Xaralambos, Harrison, Stephen A., Wong, Vincent Wai-Sun, Caldwell, Stephen H., Shiffman, Mitchell L., Camargo, Marianne, Li, Georgia, Kersey, Kathryn, Jia, Catherine, Zhu, Yanni, Djedjos, C. Stephen, Subramanian, G. Mani, Myers, Robert P., Anstee, Quentin M., Romero-Gomez, Manuel, Goodman, Zachary, Lawitz, Eric J., and Younossi, Zobair

Published
2020
Full Text
View/download PDF

32. Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study

Author

Kasai, Yuki, Kessoku, Takaomi, Tanaka, Kosuke, Yamamoto, Atsushi, Takahashi, Kota, Kobayashi, Takashi, Iwaki, Michihiro, Ozaki, Anna, Nogami, Asako, Honda, Yasushi, Ogawa, Yuji, Kato, Shingo, Imajo, Kento, Higurashi, Takuma, Hosono, Kunihiro, Yoneda, Masato, Usuda, Haruki, Wada, Koichiro, Kawanaka, Miwa, Kawaguchi, Takumi, Torimura, Takuji, Kage, Masayoshi, Hyogo, Hideyuki, Takahashi, Hirokazu, Eguchi, Yuichiro, Aishima, Shinichi, Kobayashi, Noritoshi, Sumida, Yoshio, Honda, Akira, Oyamada, Shunsuke, Shinoda, Satoru, Saito, Satoru, and Nakajima, Atsushi

Published
2022
Full Text
View/download PDF

33. Advanced fibrosis leads to overestimation of steatosis with quantitative ultrasound in individuals without hepatic steatosis

Author

Kumada, Takashi, primary, Toyoda, Hidenori, additional, Ogawa, Sadanobu, additional, Gotoh, Tatsuya, additional, Suzuki, Yasuaki, additional, Imajo, Kento, additional, Sugimoto, Katsutoshi, additional, Kakegawa, Tatsuya, additional, Kuroda, Hidekatsu, additional, Yasui, Yutaka, additional, Tamaki, Nobuharu, additional, Kurosaki, Masayuki, additional, Izumi, Namiki, additional, Akita, Tomoyuki, additional, Tanaka, Junko, additional, and Nakajima, Atsushi, additional

Published
2024
Full Text
View/download PDF

37. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study

Author

Oeda, Satoshi, Takahashi, Hirokazu, Imajo, Kento, Seko, Yuya, Ogawa, Yuji, Moriguchi, Michihisa, Yoneda, Masato, Anzai, Keizo, Aishima, Shinichi, Kage, Masayoshi, Itoh, Yoshito, Nakajima, Atsushi, and Eguchi, Yuichiro

Published
2020
Full Text
View/download PDF

39. Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease

Author

Iwaki, Michihiro, primary, Kessoku, Takaomi, additional, Tanaka, Kosuke, additional, Ozaki, Anna, additional, Kasai, Yuki, additional, Kobayashi, Takashi, additional, Nogami, Asako, additional, Honda, Yasushi, additional, Ogawa, Yuji, additional, Imajo, Kento, additional, Usuda, Haruki, additional, Wada, Koichiro, additional, Kobayashi, Noritoshi, additional, Saito, Satoru, additional, Nakajima, Atsushi, additional, and Yoneda, Masato, additional

Published
2023
Full Text
View/download PDF

40. Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography

Author

Kobayashi, Takashi, primary, Iwaki, Michihiro, additional, Nogami, Asako, additional, Kawamura, Nobuyoshi, additional, Honda, Yasushi, additional, Ogawa, Yuji, additional, Imajo, Kento, additional, Yoneda, Masato, additional, Saito, Satoru, additional, and Nakajima, Atsushi, additional

Published
2023
Full Text
View/download PDF

41. Multivariable Quantitative US Parameters for Assessing Hepatic Steatosis

Author

Kuroda, Hidekatsu, primary, Oguri, Takuma, additional, Kamiyama, Naohisa, additional, Toyoda, Hidenori, additional, Yasuda, Satoshi, additional, Imajo, Kento, additional, Suzuki, Yasuaki, additional, Sugimoto, Katsutoshi, additional, Akita, Tomoyuki, additional, Tanaka, Junko, additional, Yasui, Yutaka, additional, Kurosaki, Masayuki, additional, Izumi, Namiki, additional, Nakajima, Atsushi, additional, Fujiwara, Yudai, additional, Abe, Tamami, additional, Kakisaka, Keisuke, additional, Matsumoto, Takayuki, additional, and Kumada, Takashi, additional

Published
2023
Full Text
View/download PDF

42. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design

Author

Kessoku, Takaomi, Imajo, Kento, Kobayashi, Takashi, Honda, Yasushi, Kato, Takayuki, Ogawa, Yuji, Tomeno, Wataru, Kato, Shingo, Higurashi, Takuma, Yoneda, Masato, Kirikoshi, Hiroyuki, Kubota, Kazumi, Taguri, Masataka, Yamanaka, Takeharu, Usuda, Haruki, Wada, Koichiro, Saito, Satoru, and Nakajima, Atsushi

Published
2018
Full Text
View/download PDF

43. Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study

Author

Ozaki, Anna, Kessoku, Takaomi, Iwaki, Michihiro, Kobayashi, Takashi, Yoshihara, Tsutomu, Kato, Takayuki, Honda, Yasushi, Ogawa, Yuji, Imajo, Kento, Higurashi, Takuma, Yoneda, Masato, Taguri, Masataka, Yamanaka, Takeharu, Ishiki, Hiroto, Kobayashi, Noritoshi, Saito, Satoru, Ichikawa, Yasushi, and Nakajima, Atsushi

Published
2020
Full Text
View/download PDF

45. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study

Author

Ishiba, Hiroshi, Sumida, Yoshio, Tanaka, Saiyu, Yoneda, Masato, Hyogo, Hideyuki, Ono, Masafumi, Fujii, Hideki, Eguchi, Yuichiro, Suzuki, Yasuaki, Yoneda, Masashi, Takahashi, Hirokazu, Nakahara, Takashi, Seko, Yuya, Mori, Kojiro, Kanemasa, Kazuyuki, Shimada, Keiji, Imai, Sunsuke, Imajo, Kento, Kawaguchi, Takumi, Nakajima, Atsushi, Chayama, Kazuaki, Saibara, Toshiji, Shima, Toshihide, Fujimoto, Kazuma, Okanoue, Takeshi, Itoh, Yoshito, and for the Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD)

Published
2018
Full Text
View/download PDF

46. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Author

Abdelmalek, Manal F., primary, Sanyal, Arun J., additional, Nakajima, Atsushi, additional, Neuschwander-Tetri, Brent A., additional, Goodman, Zachary D., additional, Lawitz, Eric J., additional, Harrison, Stephen A., additional, Jacobson, Ira M., additional, Imajo, Kento, additional, Gunn, Nadege, additional, Halegoua-DeMarzio, Dina, additional, Akahane, Takemi, additional, Boone, Bradly, additional, Yamaguchi, Masayuki, additional, Chatterjee, Arkendu, additional, Tirucherai, Giridhar S., additional, Shevell, Diane E., additional, Du, Shuyan, additional, Charles, Edgar D., additional, and Loomba, Rohit, additional

Published
2023
Full Text
View/download PDF

47. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Author

Loomba, Rohit, primary, Sanyal, Arun J., additional, Nakajima, Atsushi, additional, Neuschwander-Tetri, Brent A., additional, Goodman, Zachary D., additional, Harrison, Stephen A., additional, Lawitz, Eric J., additional, Gunn, Nadege, additional, Imajo, Kento, additional, Ravendhran, Natarajan, additional, Akahane, Takemi, additional, Boone, Bradly, additional, Yamaguchi, Masayuki, additional, Chatterjee, Arkendu, additional, Tirucherai, Giridhar S., additional, Shevell, Diane E., additional, Du, Shuyan, additional, Charles, Edgar D., additional, and Abdelmalek, Manal F., additional

Published
2023
Full Text
View/download PDF

48. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography

Author

Innovative Medicines Initiative, European Commission, European Federation of Pharmaceutical Industries and Associations, NIHR Oxford Biomedical Research Centre, National Institutes of Health (US), Korea Health Industry Development Institute, National Center for Advancing Translational Sciences (US), National Institute on Alcohol Abuse and Alcoholism (US), Government of South Korea, Liang, Jia-xu, Ampuero, Javier, Niu, Hao, Imajo, Kento, Noureddin, Mazen, Behari, Jaideep, Lee, Dae Ho, Ehman, Richard L., Rorsman, Fredrik, Vessby, Johan, Lacalle, Juan R., Mózes, Ferenc E., Pavlides, Michael, Anstee, Quentin M., Harrison, Stephen A., Castell, Javier, Loomba, Rohit, Romero-Gómez, Manuel, LITMUS Consortium Investigators, Innovative Medicines Initiative, European Commission, European Federation of Pharmaceutical Industries and Associations, NIHR Oxford Biomedical Research Centre, National Institutes of Health (US), Korea Health Industry Development Institute, National Center for Advancing Translational Sciences (US), National Institute on Alcohol Abuse and Alcoholism (US), Government of South Korea, Liang, Jia-xu, Ampuero, Javier, Niu, Hao, Imajo, Kento, Noureddin, Mazen, Behari, Jaideep, Lee, Dae Ho, Ehman, Richard L., Rorsman, Fredrik, Vessby, Johan, Lacalle, Juan R., Mózes, Ferenc E., Pavlides, Michael, Anstee, Quentin M., Harrison, Stephen A., Castell, Javier, Loomba, Rohit, Romero-Gómez, Manuel, and LITMUS Consortium Investigators

Abstract

[Background & Aims] We conducted an individual patient data meta-analysis to establish stiffness cut-off values for magnetic resonance elastography (MRE) in staging liver fibrosis and to assess potential confounding factors., [Methods] A systematic review of the literature identified studies reporting MRE data in patients with NAFLD. Data were obtained from the corresponding authors. The pooled diagnostic cut-off value for the various fibrosis stages was determined in a two-stage meta-analysis. Multilevel modelling methods were used to analyse potential confounding factors influencing the diagnostic accuracy of MRE in staging liver fibrosis., [Results] Eight independent cohorts comprising 798 patients were included in the meta-analysis. The area under the receiver operating characteristic curve (AUROC) for MRE in detecting significant fibrosis was 0.92 (sensitivity, 79%; specificity, 89%). For advanced fibrosis, the AUROC was 0.92 (sensitivity, 87%; specificity, 88%). For cirrhosis, the AUROC was 0.94 (sensitivity, 88%, specificity, 89%). Cut-offs were defined to explore concordance between MRE and histopathology: ≥F2, 3.14 kPa (pretest probability, 39.4%); ≥F3, 3.53 kPa (pretest probability, 24.1%); and F4, 4.45 kPa (pretest probability, 8.7%). In generalized linear mixed model analysis, histological steatohepatitis with higher inflammatory activity (odds ratio 2.448, 95% CI 1.180–5.079, p <0.05) and high gamma-glutamyl transferase (GGT) concentration (>120U/L) (odds ratio 3.388, 95% CI 1.577–7.278, p <0.01] were significantly associated with elevated liver stiffness, and thus affecting accuracy in staging early fibrosis (F0–F1). Steatosis, as measured by magnetic resonance imaging proton density fat fraction, and body mass index(BMI) were not confounders., [Conclusions] MRE has excellent diagnostic performance for significant, advanced fibrosis and cirrhosis in patients with NAFLD. Elevated inflammatory activity and GGT level may lead to overestimation of early liver fibrosis, but anthropometric measures such as BMI or the degree of steatosis do not., [Impact and implications] This individual patient data meta-analysis of eight international cohorts, including 798 patients, demonstrated that MRE achieves excellent diagnostic accuracy for significant, advanced fibrosis and cirrhosis in patients with NAFLD. Cut-off values (significant fibrosis, 3.14 kPa; advanced fibrosis, 3.53 kPa; and cirrhosis, 4.45 kPa) were established. Elevated inflammatory activity and gamma-glutamyltransferase level may affect the diagnostic accuracy of MRE, leading to overestimation of liver fibrosis in early stages. We observed no impact of diabetes, obesity, or any other metabolic disorder on the diagnostic accuracy of MRE.

Published
2023

49. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography

Author

Imajo, Kento, Kessoku, Takaomi, Honda, Yasushi, Tomeno, Wataru, Ogawa, Yuji, Mawatari, Hironori, Fujita, Koji, Yoneda, Masato, Taguri, Masataka, Hyogo, Hideyuki, Sumida, Yoshio, Ono, Masafumi, Eguchi, Yuichiro, Inoue, Tomio, Yamanaka, Takeharu, Wada, Koichiro, Saito, Satoru, and Nakajima, Atsushi

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results